Table 1 Patient demographics and clinical characteristics

Age

50.02 ± 10.47

55.45 ± 10.52

0.005

 < 50

59 (47.97)

10 (21.28)

 50–59

41 (33.33)

21 (44.68)

 ≥ 60

23 (18.70)

16 (34.04)

BMI

24.20 ± 3.75

25.03 ± 4.43

0.347

 ≤ 18

4 (3.25)

1 (2.13)

 18–24

61 (49.59)

18 (38.30)

 > 24

58 (47.15)

28 (59.57)

Cancer type

0.210

 IDC Invasive ductal CA

114 (92.68)

39 (82.98)

 Invasive lobular CA

3 (2.44)

3 (6.38)

 Mucinous CA

5 (4.07)

3 (6.38)

 Papillar CA

1 (0.81)

2 (4.26)

pT-stage

0.188

 T1a

14 (11.38)

3 (6.38)

 T1b

13 (10.57)

8 (17.02)

 T1c

48 (39.02)

25 (53.19)

 T2

47 (38.21)

11 (23.40)

 T3–4

1 (0.81)

0 (0.00)

Tumor size (mm)

 Mean ± SD

17.18 ± 10.90

15.36 ± 7.41

0.216

 Median (IQR)

15 (11–22)

15 (10–19)

 Range

1–60

1–38

Section margin

0.161

 Negative

118 (95.93)

47 (100.00)

 Positive

5 (4.07)

0 (0.00)

Number of examed lymph node

0.030

 1–2

27 (21.95)

18 (38.30)

 3–10

77 (62.60)

27 (57.45)

 > 10

19 (15.45)

2 (4.26)

pN-stage

0.005

 N0

95 (77.24)

47 (100.00)

 N1

23 (18.70)

0 (0.00)

 N2

3 (2.44)

0 (0.00)

 N3

2 (1.63)

0 (0.00)

ER/PR status

0.281

 Negative

20 (16.26)

11 (23.40)

 Positive

103 (83.74)

36 (76.60)

Her-2 status

0.194

 Negative

96 (80.67)

41 (89.13)

 Positive

23 (19.33)

5 (10.87)

Lymphovascular invasion

0.220

 Negative

74 (60.16)

35 (74.47)

 Positive

45 (36.59)

11 (23.40)

 NA

4 (3.25)

1 (2.13)

Risk group

< 0.001

 Suitable

20 (16.26)

17 (36.17)

 Cautionary

48 (39.02)

26 (55.32)

 Unsuitable

55 (44.72)

4 (8.51)

Chemotherapy

0.082

 No

40 (32.52)

22 (46.81)

 Yes (adjuvant)

76 (61.79)

25 (53.19)

 Yes (neoadjuvant)

7 (5.69)

0 (0.00)

Hormone therapy

0.324

 No

23 (18.70)

12 (25.53)

 Yes

100 (81.30)

35 (74.47)

Target therapy

0.194

 No

110 (89.43)

45 (95.74)

 Yes

13 (10.57)

2 (4.26)

Follow-up time

3.67 ± 0.82

3.18 ± 0.69

< 0.001